Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion

BMC Cancer

Ana C V Krepischi⁴  Carla Rosenberg⁵  Maria Isabel W Achatz⁶  Patricia Ashton-Prolla²  Manuel R Teixeira¹  Dirce M Carraro⁶  Amanda França de Nóbrega⁷  Ana Peixoto⁸  Manuela Pinheiro⁸  Marina Sapienza⁵  Ingrid Petroni Ewald³  Amanda Gonçalves Silva⁶ 

[1]Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal

[2]Department of Genetics and Post-Graduate Program in Genetics and Molecular Biology, Federal University of Rio Grande do Sul and Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

[3]Post-Graduate Course in Medicine, Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

[4]Hospital A. C. Camargo, Rua Taguá, 440 – Liberdade – CEP 01508-010, São Paulo, Brazil

[5]Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, Brazil

[6]National Institute of Science and Technology in Oncogenomics, São Paulo, Brazil

[7]International Center for Research and Training, A. C. Camargo Cancer Hospital, São Paulo, Brazil

[8]Department of Genetics, Portuguese Oncology Institute, Porto, Portugal

关键词: Li-Fraumeni syndrome;    BRCA1 microdeletion;    MLPA;    Copy number variation;    Breast cancer;   

Others  :  1080370
DOI  :  10.1186/1471-2407-12-237

 received in 2012-01-30, accepted in 2012-05-24,  发布年份 2012

【 摘 要 】

Background

Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) syndromes are associated to germline TP53 mutations, and are characterized by the development of central nervous system tumors, sarcomas, adrenocortical carcinomas, and other early-onset tumors. Due to the high frequency of breast cancer in LFS/LFL families, these syndromes clinically overlap with hereditary breast cancer (HBC). Germline point mutations in BRCA1, BRCA2, and TP53 genes are associated with high risk of breast cancer. Large rearrangements involving these genes are also implicated in the HBC phenotype.

Methods

We have screened DNA copy number changes by MLPA on BRCA1, BRCA2, and TP53 genes in 23 breast cancer patients with a clinical diagnosis consistent with LFS/LFL; most of these families also met the clinical criteria for other HBC syndromes.

Results

We found no DNA copy number alterations in the BRCA2 and TP53 genes, but we detected in one patient a 36.4 Kb BRCA1 microdeletion, confirmed and further mapped by array-CGH, encompassing exons 9–19. Breakpoints sequencing analysis suggests that this rearrangement was mediated by flanking Alu sequences.

Conclusion

This is the first description of a germline intragenic BRCA1 deletion in a breast cancer patient with a family history consistent with both LFL and HBC syndromes. Our results show that large rearrangements in these known cancer predisposition genes occur, but are not a frequent cause of cancer susceptibility.

【 授权许可】

   
2012 Silva et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250(4985):1233-1238.
• [2]Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48(18):5358-5362.
• [3]Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM: Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001, 20(34):4621-4628.
• [4]Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP, Santibáñez-Koref MF: Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 1994, 70(6):1176-1181.
• [5]Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J, Li FP, Friend SH: Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995, 56(3):608-615.
• [6]Rapakko K, Allinen M, Syrjäkoski K, Vahteristo P, Huusko P, Vähäkangas K, Eerola H, Kainu T, Kallioniemi OP, Nevanlinna H, et al.: Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 2001, 84(1):116-119.
• [7]Lindor NM, McMaster ML, Lindor CJ, Greene MH, National Cancer Institute DoCP C.mmunity Oncology and Prevention Trials Research Group: Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008, 38:1-93.
• [8]Huusko P, Castrén K, Launonen V, Soini Y, Pääkkönen K, Leisti J, Vähäkangas K, Winqvist R: Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2. Cancer Genet Cytogenet 1999, 112(1):9-14.
• [9]Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, Shields PG, Modali R, Turner BC: Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000, 60(4):1062-1069.
• [10]Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, Evans DG, Group EOBCS: Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003, 361(9363):1101-1102.
• [11]Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, et al.: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295(12):1379-1388.
• [12]Easton DF: How many more breast cancer predisposition genes are there? Breast Cancer Res 1999, 1(1):14-17. BioMed Central Full Text
• [13]Chompret A: Clinical and molecular diagnosis of inherited breast-ovarian cancer. J Gynecol Obstet Biol Reprod (Paris) 2003, 32(2):101-119.
• [14]Hirshfield KM, Rebbeck TR, Levine AJ: Germline mutations and polymorphisms in the origins of cancers in women. J Oncol 2010, 2010:297671.
• [15]Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D: Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992, 52(11):3234-3236.
• [16]Evans DG, Wu CL, Birch JM: BRCA2: a cause of Li-Fraumeni-like syndrome. J Med Genet 2008, 45(1):62-63.
• [17]Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, Stacchiotti S, Terenziani M, Barbera F, Pasquini G, Frigerio S, et al.: Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 2007, 43(3):601-606.
• [18]Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, et al.: BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006, 42(8):1143-1150.
• [19]Kuiper RP, Ligtenberg MJ, Hoogerbrugge N, Geurts van Kessel A: Germline copy number variation and cancer risk. Curr Opin Genet Dev 2010, 20(3):282-289.
• [20]Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D'Andrea E: Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet 2003, 12(9):1055-1061.
• [21]Woodward A, Davis T, Silva A, Kirk J, Leary J, Investigators K: Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet 2005, 42(5):e31.
• [22]Hansen TO, Jønson L, Albrechtsen A, Andersen MK, Ejlertsen B, Nielsen FC: Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. Breast Cancer Res Treat 2009, 115(2):315-323.
• [23]Hartmann C, John AL, Klaes R, Hofmann W, Bielen R, Koehler R, Janssen B, Bartram CR, Arnold N, Zschocke J: Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum Mutat 2004, 24(6):534.
• [24]IARC - INTERNATIONAL AGENCY FOR RESEARCH ON CANCER[http://www.iarc.fr]
• [25]Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28(6):622-629.
• [26]Tournier I, Paillerets BB, Sobol H, Stoppa-Lyonnet D, Lidereau R, Barrois M, Mazoyer S, Coulet F, Hardouin A, Chompret A, et al.: Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 2004, 64(22):8143-8147.
• [27]Agata S, Dalla Palma M, Callegaro M, Scaini MC, Menin C, Ghiotto C, Nicoletto O, Zavagno G, Chieco-Bianchi L, D'Andrea E, et al.: Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet 2005, 42(10):e64.
• [28]Pavlicek A, Noskov VN, Kouprina N, Barrett JC, Jurka J, Larionov V: Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition. Hum Mol Genet 2004, 13(22):2737-2751.
• [29]Gad S, Klinger M, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, Bensimon A, Aurias A, Stoppa-Lyonnet D: Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families. J Med Genet 2002, 39(11):817-821.
• [30]Mazoyer S: Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 2005, 25(5):415-422.
• [31]Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy FeS, Kohlrausch F, Magno LA, Montenegro RC, Moraes MO, et al.: The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 2011, 6(2):e17063.
• [32]Li FP, Fraumeni JF: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969, 71(4):747-752.
• [33]Eeles RA: Germline mutations in the TP53 gene. Cancer Surv 1995, 25:101-124.
• [34]Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, et al.: P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000, 82(12):1932-1937.
• [35]Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pagés S, Feunteun J, Bonaïti-Pellié C: Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001, 38(1):43-47.
• [36]Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, et al.: The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007, 245(1–2):96-102.
• [37]NCCN - National Comprehensive Cancer Network[http://www.nccn.org]
• [38]Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002, 30(12):e57.
• [39]Shlien A, Baskin B, Achatz MI, Stavropoulos DJ, Nichols KE, Hudgins L, Morel CF, Adam MP, Zhukova N, Rotin L, et al.: A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes. Am J Hum Genet 2010, 87(5):631-642.
• [40]Krepischi A, Achatz M, Santos E, Costa S, Lisboa B, Brentani H, Santos T, Gonçalves A, Nóbrega A, Pearson P, et al.: Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res 2012. in press